Inventor · disambiguated record
Jacques Banville
Also filed as: BANVILLE JACQUES
27 granted patents·2 pending applications·412 citations·filing 1995–2024
97Inventor score
Top patents by PatentIndex Score
29 records- 0195US7157447B2Bicyclic heterocycles as HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Jan 2, 2007·30 cites·5 claims
- 0294US7176196B2Bicyclic heterocycles as HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Feb 13, 2007·35 cites·27 claims
- 0394US6350892B1Trifluoromethyl ketone analogs as selective cPLA2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Feb 26, 2002·41 cites·8 claims
- 0493US10047103B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 14, 2018·11 cites·22 claims
- 0593US7192948B2Bicyclic heterocycles as HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Mar 20, 2007·34 cites·14 claims
- 0693US7173022B2Bicyclic heterocycles as HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Feb 6, 2007·31 cites·14 claims
- 0792US10822343B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 3, 2020·4 cites·15 claims
- 0892US10428077B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Oct 1, 2019·8 cites·9 claims
- 0990US10214544B2Imidazopyridazine and imidazothiadiazole compoundsUNIV MONTREAL·Filed 2016·Granted Feb 26, 2019·5 cites·18 claims
- 1090US9688695B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jun 27, 2017·11 cites·51 claims
- 1189US12060353B2Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative diseaseUNIV MONTREAL·Filed 2023·Granted Aug 13, 2024·3 cites·29 claims
- 1289US7109186B2HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 19, 2006·27 cites·11 claims
- 1388US6414179B1Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Jul 2, 2002·32 cites·9 claims
- 1486US9862730B2Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 9, 2018·5 cites·11 claims
- 1585US7511037B2N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitorBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Mar 31, 2009·7 cites·4 claims
- 1685US5663151ASulfated α-glycolipid derivatives as cell adhesion inhibitorsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Sep 2, 1997·68 cites·42 claims
- 1785US2025002497A1Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1884US7494984B2Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 24, 2009·8 cites·14 claims
- 1980US12084452B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 10, 2024·0 cites·6 claims
- 2080US6777440B2HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Aug 17, 2004·14 cites·19 claims
- 2178US7893055B2HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Feb 22, 2011·4 cites·7 claims
- 2278US6890942B2Acyl sulfonamides as inhibitors of HIV integraseBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 10, 2005·9 cites·13 claims
- 2376US12479842B2Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative diseaseUNIV MONTREAL·Filed 2022·Granted Nov 25, 2025·0 cites·22 claims
- 2475US8039458B2HIV integrase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Oct 18, 2011·2 cites·14 claims
- 2568US6492550B2Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Dec 10, 2002·1 cites·9 claims
- 2660US6924391B2Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Aug 2, 2005·2 cites·2 claims
- 2757US6255496B1Trifluoromethyl ketone analogs as selective cPLA2 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Jul 3, 2001·15 cites·34 claims
- 2844US5565433ASulfated β-glycolipid derivatives as cell adhesion inhibitorsBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Oct 15, 1996·5 cites·38 claims
- 2944US2005043370A1HIV integrase inhibitorsFiled 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jacques Banville files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →